logo

For the Inventor, By the Inventor

Boulder, CO, United States of America

Christina Marie Dalby

USPTO Granted Patents = 16 

Average Co-Inventor Count = 3.5

ph-index = 5

Forward Citations = 46(Granted Patents)


Company Filing History:

goldMedal16 out of 20 
 
Miragen Therapeutics, Inc.
 patents

Years Active: 2014-2019

Loading Chart...
16 patents (USPTO):Explore Patents
1. 10337005 - Oligonucleotide-based inhibitors comprising locked nucleic acid motif (2019-07-02),
2. 10316318 - Oligonucleotide compositions and uses thereof (2019-06-11),
3. 10280422 - MiR-92 inhibitors and uses thereof (2019-05-07),
4. 10144930 - Inhibitors of MYH7B and uses thereof (2018-12-04),
5. 9994852 - Oligonucleotide compositions and uses thereof (2018-06-12),
6. 9994847 - miR-29 mimics and uses thereof (2018-06-12),
7. 9885042 - miR-92 inhibitors and uses thereof (2018-02-06),
8. 9803202 - Oligonucleotide-based inhibitors comprising locked nucleic acid motif (2017-10-31),
9. 9771585 - miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL) (2017-09-26),
10. 9752144 - Inhibitors of MYH7B and uses thereof (2017-09-05),
11. 9752143 - Locked nucleic acid inhibitor of miR-145 and uses thereof (2017-09-05),
12. 9416360 - Base modified oligonucleotides (2016-08-16),
13. 9388408 - Oligonucleotide-based inhibitors comprising locked nucleic acid motif (2016-07-12),
14. 9376681 - miR-29 mimics and uses thereof (2016-06-28),
15. 9163235 - Inhibitors of the miR-15 family of micro-RNAs (2015-10-20),

Title: Christina Marie Dalby: Innovator in Oligonucleotide Therapeutics

Introduction

Christina Marie Dalby is a prominent inventor based in Boulder, Colorado. She has made significant contributions to the field of oligonucleotide-based therapeutics, holding a total of 16 patents. Her work focuses on developing innovative solutions for various medical disorders, particularly in the realm of cancer treatment.

Latest Patents

Among her latest patents is the invention titled "Oligonucleotide-based inhibitors comprising locked nucleic acid motif." This invention relates to chemical modification motifs for oligonucleotides, which can enhance in vivo efficacy. The chemically modified antisense oligonucleotides offer advantages in potency, delivery efficiency, target specificity, toxicity, and stability. These oligonucleotides can target RNA, including miRNA or mRNA, and are designed for therapeutic applications in treating cardiovascular disorders. Another notable patent is "Oligonucleotide compositions and uses thereof," which provides oligonucleotide inhibitors of miR-155. This invention outlines methods for treating cancers, such as T cell lymphoma, by administering oligonucleotide inhibitors to reduce the proliferation of malignant T cells.

Career Highlights

Christina is currently associated with Miragen Therapeutics, Inc., where she continues to advance her research and development efforts. Her innovative work has positioned her as a key figure in the biotechnology sector, particularly in the development of oligonucleotide-based therapies.

Collaborations

Throughout her career, Christina has collaborated with notable professionals in her field, including Rusty L Montgomery and Eva Van Rooij. These collaborations have further enriched her research and contributed to the advancement of therapeutic innovations.

Conclusion

Christina Marie Dalby is a trailblazer in the field of oligonucleotide therapeutics, with a strong portfolio of patents that reflect her commitment to improving medical treatments. Her contributions are paving the way for new therapeutic options in the fight against various disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…